CompletedNot Applicable

Two-session Catheter-directed Sclerotherapy Using Ethanol for Endometrioma

South Korea22 participantsStarted 2020-06-01

Plain-language summary

The goal of this clinical trial is to evaluate the safety and clinical outcomes of two-session catheter-directed sclerotherapy (CDS) with 96% ethanol in patients with endometrioma. The main question it aims to answer is: • Is two-session CDS with 96% ethanol safe and effective for treating endometrioma? Participants will: * Receive the first session CDS for endometrioma * Carry the catheter overnight and be monitored in the patient ward * Receive the second session CDS the next day

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged ≥ 18 years * Symptom manifestation as endometriosis (i.e., dysmenorrhea, dyspareunia, and lower abdominal or pelvic pain) * Endometrioma ≥ 3 cm confirmed on ultrasound * No evidence of solid lesions on ultrasound * No suspected extraovarian endometriosis Exclusion Criteria: * History of gynecologic malignancy * Active inflammation or infection * Abnormal coagulation profile * Loss to follow-up

What they're measuring

Recurrence

Timeframe: Recurrence was assessed at 1, 3, and 6 months after the procedure.

Trial details

NCT IDNCT06274086

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-31

View on ClinicalTrials.gov More Sclerotherapy trials